Clinical Trial Update: Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC [Phase 2, Phase 3]

View source ↗

Summary

A double-blind, randomized, placebo-controlled study evaluating EUFLEXXA for osteoarthritis of the first carpometacarpal joint has completed (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Euflexxa (sodium hyaluronate)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Osteoarthritis | Phase 2, Phase 3 | Status: COMPLETED